Skip to main content
. 2010 Aug 31;18(11):1927–1936. doi: 10.1038/mt.2010.183

Figure 4.

Figure 4

Combination therapy with rapamycin promotes JX-594/JX-594m oncolysis in vitro and in vivo. (a) Kaplan–Meier survival of intracranial RG2-bearing rats after treatment with PBS (n = 4), JX-594 alone (n = 6), rapamycin alone (n = 4), or a combination of both JX-594 and rapamycin (n = 6, log-rank test, P < 0.0001 compared to PBS). (b) Kaplan–Meier survival of “advanced” intracranial RG2 tumor-bearing rats after treatment with PBS (n = 6), JX-594m alone (n = 7), rapamycin alone (n = 6), or a combination of both JX-594m and rapamycin (n = 7, log-rank test, P < 0.0001 compared to PBS). (c) Survival of intracranial GL261 tumor-bearing mice after treatment with PBS (n = 5), JX-594 alone (n = 7), rapamycin alone (n = 5), or a combination of both JX-594 and rapamycin (n = 7, log-rank test, P < 0.0001 compared to PBS). (d) Kaplan–Meier survival of “advanced” intracranial GL261 tumor-bearing mice after treatment with PBS (n = 6), JX-594m alone (n = 6), rapamycin alone (n = 6), or a combination of both JX-594m and rapamycin (n = 7, log-rank test, P = 0.1524 compared to PBS). PBS, phosphate-buffered saline; Rap, rapamycin.